Back to top

Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform

As previously reported, Wells Fargo analyst Derek Archila upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with a price target...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viridian Therapeutics, Inc. (VRDN)